Obesity: A template to trigger metabolic syndromes and carcinoma. Metformin: A drug target
CONCLUSION: Primarily, co-morbidities of human obesity start with insulin resistance and then multiplies with metabolic irregularities. The drug metformin has bi-functional potential. It can increase insulin sensitivity in one hand, and can prevent tumorigenic incursion on other hand.PMID:33906589 | DOI:10.2174/1389450122666210427125348
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Nimai Chand Chandra Source Type: research
More News: Cancer & Oncology | Carcinoma | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Fortamet | Insulin | Metabolic Syndrome | Metformin | Obesity